In vitro antifungal activity of micafungin;Actividad antifúngica in vitro de la micafungina

Revista Iberoamericana de Micologia

Volumn 26, Issue 1, 2009, Pages 35-41

  Quindós, Guillermo ^a   Eraso, Elena ^a   Javier Carrillo Muñoz, Alfonso ^b   Cantón, Emilia ^c   Pemán, Javier ^c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Associacio Catalana d'Intelligencia Artificial   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antifungal agents; Aspergillus; Candida; In vitro activity; Micafungin; Moulds; Yeasts

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN Z; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CRYPTOCOCCUS; FUNGUS ISOLATION; IN VITRO STUDY; INVASIVE CANDIDIASIS; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; ZYGOMYCETES;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; ECHINOCANDINS; FUNGI; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MYCOSES; SPECIES SPECIFICITY;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; FUNGI; ISSATCHENKIA ORIENTALIS; PICHIA GUILLIERMONDII; ZYGOMYCETES;

EID: 67650725977     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(09)70006-3     Document Type: Review

References (101)

1. Angiolella L., Maras B., Stringaro A.R., Arancia G., Mondello F., Girolamo A., Palamara A.T., and Cassone A. Glucan-associated protein modulations and ultrastructural changes of the cell wall in Candida albicans treated with micafungin, a water-soluble, lipopeptide antimycotic. J Chemother 17 (2005) 409-416
2. Aperis G., Myriounis N., Spanakis E.K., and Mylonakis E. Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Investig Drugs 15 (2006) 1319-1336
3. Arathoon E.G. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 14 (2001) 685-691
4. Asada N., Uryu H., Koseki M., Takeuchi M., Komatsu M., and Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 43 (2006) e39-e41
5. Baixench M.T., Aoun N., Arsnos-Ollivier M., Garcia-Hermoso D., Bretagne S., Ramires S., Piketty C., and Dannaoui E. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59 (2007) 1076-1083
6. Bartlett M.S., Current W.L., Goheen M.P., Boylan C.J., Lee C.H., Shaw M.M., Queener S.F., and Smith J.W. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 40 (1996) 1811-1816
7. Brun Y.F., Dennis C.G., Greco W.R., Bernacki R.J., Pera P.J., Bushey J.J., Youn R.C., White D.B., and Segal B.H. Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm. Antimicrob Agents Chemoth 51 (2007) 1804-1812
8. Canton E., Peman J., Sastre M., Romero M., and Espinel-Ingroff A. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemothe 50 (2006) 2829-2832
9. Cao C., Liu W., Li R., Wan Z., and Qiao J. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei. J Antimicrob Chemother 63 (2009) 340-342
10. Cappelletty D., and Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 27 (2007) 369-388
11. Carrillo-Munoz A.J., Giusiano G., Ezkurra P.A., and Quindós G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 19 (2006) 130-139
12. Cateau E., Rodier M.H., and Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 62 (2008) 153-155
13. Chamilos G., Lewis R.E., Albert N., and Kontoyiannis D.P. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother 51 (2007) 2257-2259
14. Chiou C.C., Mavrogiorgos N., Tillem E., Hector R., and Walsh T.J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 45 (2001) 3310-3321
15. Choi H.W., Shin J.H., Jung S.I., Park K.H., Cho D., Kee S.J., Shin M.G., Suh S.P., and Ryang D.W. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 51 (2007) 1520-1523
16. Choi H.W., Shin J.H., Lee J.S., Cho D., Shin M.G., Suh S.P., and Ryang D.W. In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species. Korean J Lab Med 26 (2006) 275-281
17. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. Document M38-A2. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
18. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27- [3A] ed 3rd. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
19. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third Informational Supplement. Document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
20. Dannaoui E., Lortholary O., Raoux D., Bougnoux M.E., Galeazzi G., Lawrence C., Moissenet D., Poilane I., Hoinard D., and Dromer F. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother 52 (2008) 778-781
21. De Pauw B.E., and Picazo J.J. Present situation in the treatment of invasive fungal infection. Int J Antimicrob Agents 32 Suppl 2 (2008) S167-S171
22. De Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della N.M., and Diekmann- Berndt H. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39 (2004) 842-849
23. De Wet N.T., Bester A.J., Viljoen J.J., Filho F., Suleiman J.M., Ticona E., Llanos E.A., Fisco C., Lau W., and Buell D. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21 (2005) 899-907
24. Del Palacio A., Villar J., and Alhambra A. Epidemiología de las candidiasis invasoras en población pediátrica y adulta. Rev Iberoam Micol 26 (2009) 2-7
25. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol 20 (2003) 121-136
26. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 25 (2008) 101-106
27. Fleischhacker M., Radecke C., Schulz B., and Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 27 (2008) 127-131
28. Ganesan L.T., Manavathu E.K., Cutright J.L., Alangaden G.J., and Chandrasekar P.H. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin Microbiol Infect 10 (2004) 961-966
29. Garcia-Effron G., Katiyar S.K., Park S., Edlind T.D., and Perlin D.S. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52 (2008) 2305-2312
30. Garcia-Effron G., Park S., and Perlin D.S. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53 (2009) 112-122
31. Gilgado F., Serena C., Cano J., Gene J., and Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 50 (2006) 4211-4213
32. Girish Kumar C.P., Hanafy A.M., Katsu M., Mikami Y., and Menon T. Molecular analysis and susceptibility profiling of Candida albicans isolates from immunocompromised patients in South India. Mycopathologia 161 (2006) 153-159
33. Groll AH, McNeil GL. Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host: Thessaloniki, Greece, 22-25 June 2008. Int J Antimicrob Agents 2009;33:101-104.
34. Guinea J., Pelaez T., Alcala L., Ruiz-Serrano M.J., and Bouza E. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob Agents Chemother 49 (2005) 3495-3497
35. Hakki M., Staab J.F., and Marr K.A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50 (2006) 2522-2524
36. Haruyama N., Masutani K., Tsuruya K., Sugiwaka S., Toyonaga J., Yao T., Goto K., Tokumoto M., Hirakata H., and Iida M. Candida glabrata fungemia in a diabetic patient with neurogenic bladder: successful treatment with micafungin. Clin Nephrol 66 (2006) 214-217
37. Hashimoto H., Moriya R., Kamata K., Higashihara M., Yoshida K., and Kume H. Successful treatment with micafungin (MCFG) of severe peritonitis due to Candida parapsilosis with chronic renal failure patient on hemodialysis. Kansenshogaku Zasshi 79 (2005) 195-200
38. Heyn K., Tredup A., Salvenmoser S., and Muller F.M. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 49 (2005) 5157-5159
39. Ikeda F., Saika T., Sato Y., Suzuki M., Hasegawa M., Mikawa T., Kobayashi I., and Tsuji A. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med Mycol. 47 (2009) 145-148
40. Jacobsen M.D., Whyte J.A., and Odds F.C. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 51 (2007) 1882-1884
41. Jarvis B., Figgitt D.P., and Scott L.J. Micafungin. Drugs 64 (2004) 969-982
42. Kahn J.N., Garcia-Effron G., Hsu M.J., Park S., Marr K.A., and Perlin D.S. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 51 (2007) 1876-1878
43. Katragkou A., Chatzimoschou A., Simitsopoulou M., Dalakiouridou M., Dizaza- Mataftsi E., Tsantali C., and Roilides E. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 52 (2008) 357-360
44. Kim R., Khachikian D., and Reboli A.C. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 8 (2007) 1479-1492
45. Kim S.H., Shin J.H., Kim E.C., Lee K., Kim M.N., Lee W.G., Uh Y., Lee H.S., Lee M.K., Jeong S.H., Jung S.I., Park K.H., Lee J.S., Shin M.G., Suh S.P., and Ryang D.W. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol (2008) 1-9
46. Kontoyiannis D.P., Ratanatharathorn V., Young J.A., Raymond J., Laverdiere M., Denning D.W., Patterson T.F., Facklam D., Kovanda L., Arnold L., Lau W., Buell D., and Marr K.A. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 11 (2009) 89-93
47. Krogh-Madsen M., Arendrup M.C., Heslet L., and Knudsen J.D. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 42 (2006) 938-944
48. Kuhn D.M., George T., Chandra J., Mukherjee P.K., and Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46 (2002) 1773-1780
49. Kuse E.R., Chetchotisakd P., Da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., Sekhon J.S., Freire A., Ramasubramanian V., Demeyer I., Nucci M., Leelarasamee A., Jacobs F., Decruyenaere J., Pittet D., Ullmann A.J., Ostrosky-Zeichner L., Lortholary O., Koblinger S., ekmann-Berndt H., and Cornely O.A. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double- blind trial. Lancet 369 (2007) 1519-1527
50. Laverdiere M., Hoban D., Restieri C., and Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50 (2002) 119-123
51. Laverdiere M., Labbe A.C., Restieri C., Rotstein C., Heyland D., Madger S., and Stewart T. Susceptibility patterns of Candida species recovered from Canadian intensive care units. J Crit Care 22 (2007) 245-250
52. Lee J.S., Shin J.H., Kim M.N., Jung S.I., Park K.H., Cho D., Kee S.J., Shin M.G., Suh S.P., and Ryang D.W. Kodamaea ohmeri isolates from patients in a university hospital: identification, antifungal susceptibility, and pulsed-field gel electrophoresis analysis. J Clin Microbiol 45 (2007) 1005-1010
53. Lewis R.E., and Kontoyiannis D.P. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 56 (2005) 887-892
54. Lockhart S.R., Messer S.A., Pfaller M.A., and Diekema D.J. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 46 (2008) 2659-2664
55. Lockhart S.R., Messer S.A., Pfaller M.A., and Diekema D.J. Identification and Susceptibility Profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol 47 (2009) 242-244
56. Marine M., Serena C., Pastor J., Quindos G., Carrillo A.J., and Guarro J. In vitro activity of micafungin combined with itraconazole against Candida spp. Int J Antimicrob Agents 30 (2007) 463-465
57. Matsue K., Uryu H., Koseki M., Asada N., and Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 42 (2006) 753-757
58. Messer S.A., Diekema D.J., Boyken L., Tendolkar S., Hollis R.J., and Pfaller M.A. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 44 (2006) 324-326
59. Mitsuyama J., Nomura N., Hashimoto K., Yamada E., Nishikawa H., Kaeriyama M., Kimura A., Todo Y., and Narita H. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother 52 (2008) 1318-1324
60. Moudgal V., Little T., Boikov D., and Vazquez J.A. Multiechinocandin- and multiazoleresistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49 (2005) 767-769
61. Nakamura T., and Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother 12 (2006) 132-138
62. Nishiyama Y., Hasumi Y., Ueda K., Uchida K., and Yamaguchi H. Effects of micafungin on the morphology of Aspergillus fumigatus. J Electron Microsc (Tokyo) 54 (2005) 67-77
63. Nishiyama Y., Uchida K., and Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 51 (2002) 247-255
64. Oliveira E.R., Fothergill A., Kirkpatrick W.R., Patterson T.F., and Redding S.W. Antifungal susceptibility testing of micafungin against Candida glabrata isolates. Oral Surg Oral Med Oral Pathol Oral Radiol Endo 105 (2008) 457-459
65. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
66. Pai M.P., Jones A.L., and Mullen C.K. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Diagn Microbiol Infect Dis 58 (2007) 129-132
67. Pai M.P., Samples M.L., Mercier R.C., and Spilde M.N. Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations. Antimicrob Agents Chemother 52 (2008) 2367-2376
68. Pastor F.J., and Guarro J. Micafungina en el tratamiento de la infección fúngica en modelos animales. Rev Iberoam Micol 26 (2009) 42-48
69. Pelletier R., Alarie I., Lagace R., and Walsh T.J. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 43 (2005) 559-564
70. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
71. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., and Diekema D.J. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 44 (2006) 3533-3538
72. Pfaller M.A., Chaturvedi V., Diekema D.J., Ghannoum M.A., Holliday N.M., Killian S.B., Knapp C.C., Messer S.A., Miskov A., and Ramani R. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol 46 (2008) 2155-2159
73. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Nagy E., Dobiasova S., Rinaldi M., Barton R., and Veselov A. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46 (2008) 515-521
74. Pfaller M.A., Diekema D.J., Gibbs D.L., Newell V.A., Ng K.P., Colombo A., Finquelievich J., Barnes R., and Wadula J. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 46 (2008) 842-849
75. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., Rex J.H., Alexander B.D., Andes D., Brown S.D., Chaturvedi V., Ghannoum M.A., Knapp C.C., Sheehan D.J., and Walsh T.J. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46 (2008) 2620-2629
76. Pontón J. La pared celular de los hongos y el mecanismo de acción de la anidulafungina. Rev Iberoam Micol 25 (2008) 78-82
77. Quindós G., Carrillo-Muñoz A.J., Eraso E., Cantón E., and Pemán J. Actividad antifúngica in vitro de voriconazol: Nuevos datos después de los primeros años de experiencia clínica. Rev Iberoam Micol 24 (2007) 198-208
78. Quindós G., and Eraso E. Actividad antifúngica in vitro de la anidulafungina. Rev Iberoam Micol 25 (2008) 83-91
79. Quindós G., Villar-Vidal M., and Eraso E. Actividad de la micafungina contra las biopelículas fúngicas. Rev Iberoam Micol 29 (2009) 49-55
80. Ramirez M., Serrano M.C., Castro C., Lopez E., Almeida C., Fernandez A., Romero A., and Martin-Mazuelos E. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species. J Antimicrob Chemother 58 (2006) 861-863
81. Rautemaa R., Richardson M., Pfaller M.A., Perheentupa J., and Saxen H. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis 62 (2008) 182-185
82. Richards T.S., Oliver B.G., and White T.C. Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J Antimicrob Chemother 62 (2008) 349-355
83. Rodriguez M.M., Ruiz M., Pastor F.J., Quindós G., Carrillo A., and Guarro J. In vitro interaction of micafungin and fluconazole against Candida. J Antimicrob Chemother 60 (2007) 188-190
84. Ruan S.Y., Chu C.C., and Hsueh P.R. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrob Agents Chemother 52 (2008) 2919-2922
85. Ruiz-Cendoya M., Rodriguez M.M., Marine M., Pastor F.J., and Guarro J. In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi. Int J Antimicrob Agents 32 (2008) 418-420
86. Seidler M., Salvenmoser S., and Muller F.M. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int J Antimicrob Agents 28 (2006) 568-573
87. Serena C., Fernandez-Torres B., Pastor F.J., Trilles L., Lazera M.S., Nolard N., and Guarro J. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother 49 (2005) 2994-2996
88. Serena C., Marine M., Pastor F.J., Nolard N., and Guarro J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother 55 (2005) 1020-1023
89. Serena C., Marine M., Quindós G., Carrillo A.J., Cano J.F., Pastor F.J., and Guarro J. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. Antimicrob Agents Chemother 52 (2008) 1529-1532
90. Serena C., Ortoneda M., Capilla J., Pastor F.J., Sutton D.A., Rinaldi M.G., and Guarro J. In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob Agents Chemother 47 (2003) 3161-3164
91. Serena C., Pastor F.J., Ortoneda M., Capilla J., Nolard N., and Guarro J. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob Agents Chemother 48 (2004) 2724-2726
92. Sugita T., Takashima M., Poonwan N., and Mekha N. Candida pseudohaemulonii Sp. Nov., an amphotericin B-and azole-resistant yeast species, isolated from the blood of a patient from Thailand. Microbiol Immunol 50 (2006) 469-473
93. Sugita T., Takeo K., Ohkusu M., Virtudazo E., Takashima M., Asako E., Ohshima F., Harada S., Yanaka C., Nishikawa A., Majoros L., and Sipiczki M. Fluconazole-resistant pathogens Candida inconspicua and C. norvegensis: DNA sequence diversity of the rRNA intergenic spacer region, antifungal drug susceptibility, and extracellular enzyme production. Microbiol Immunol 48 (2004) 761-766
94. Trilles L., Fernandez-Torres B., Lazera M.S., Wanke B., and Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 42 (2004) 4815-4817
95. Trofa D., Gacser A., and Nosanchuk J.D. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 21 (2008) 606-625
96. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., Stevens D.A., van Burik J.A., Wingard J.R., and Patterson T.F. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
97. Warn P.A., Morrissey G., Morrissey J., and Denning D.W. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 51 (2003) 913-919
98. Warn P.A., Sharp A., Guinea J., and Denning D.W. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother 53 (2004) 743-749
99. Yarita K., Sano A., Murata Y., Takayama A., Takahashi Y., Takahashi H., Yaguchi T., Ohori A., Kamei K., Miyaji M., and Nishimura K. Pathogenicity of Ochroconis gallopava isolated from hot springs in Japan and a review of published reports. Mycopathologia 164 (2007) 135-147
100. Yustes C., and Guarro J. In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother 49 (2005) 3498-3500
101. Zeng J., Kamei K., Zheng Y., and Nishimura K. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents. Nippon Ishinkin Gakkai Zasshi 45 (2004) 101-104